A study of the pharmacodynamic differences between immediate and extended release bumetanide formulations

Author： Hamed E. Gerson M.C. Millard R.W. Sakr A.

Publisher： Elsevier

ISSN： 0378-5173

Source： International Journal of Pharmaceutics, Vol.267, Iss.1, 2003-11, pp. : 129-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bioavailability of Immediate- and Extended-Release Formulations of Glipizide in Healthy Male Volunteers

By Dhawan Sanju

Clinical Pharmacokinetics, Vol. 45, Iss. 3, 2006-01 ,pp. : 317-324

Adis International

Access to resources Recommend Favorite

Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg

By Leufkens Tim Vermeeren Annemiek Smink Beitske Ruitenbeek Peter Ramaekers Johannes

Psychopharmacology, Vol. 191, Iss. 4, 2007-05 ,pp. : 951-959

Springer Publishing Company

Access to resources Recommend Favorite

Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate: A Chart Review of Spanish Adults with Attention-Deficit Hyperactivity Disorder

By Josep Antoni Ramos-Quiroga Bosch Rosa Castells Xavier Valero Sergi Nogueira Mariana Gómez Nuria Yelmo Silvia Ferrer Marc Martínez Yolanda Casas Miguel

CNS Drugs, Vol. 22, Iss. 7, 2008-01 ,pp. : 603-611

Adis International

Access to resources Recommend Favorite

Photostability of extended-release matrix formulations

By Maggi L. Ochoa Machiste E. Fasani E. Albini A. Segale L. Conte U.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 55, Iss. 1, 2003-01 ,pp. : 99-105

Elsevier

Access to resources Recommend Favorite

Extended-Release Formulations for the Treatment of Epilepsy

By Bialer Meir

CNS Drugs, Vol. 21, Iss. 9, 2007-01 ,pp. : 765-774

Adis International

Access to resources Recommend Favorite